• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Med . SARS-CoV-2 correlates of protection from infection against variants of concern

tetano

Editor, Senior Moderator
Nat Med


. 2024 Jul 26.
doi: 10.1038/s41591-024-03131-2. Online ahead of print. SARS-CoV-2 correlates of protection from infection against variants of concern

Kaiyuan Sun[SUP] #[/SUP][SUP] 1 [/SUP], Jinal N Bhiman[SUP] #[/SUP][SUP] 2 3 [/SUP], Stefano Tempia[SUP] 4 5 6 [/SUP], Jackie Kleynhans[SUP] 4 5 [/SUP], Vimbai Sharon Madzorera[SUP] 2 3 [/SUP], Qiniso Mkhize[SUP] 2 3 [/SUP], Haajira Kaldine[SUP] 2 3 [/SUP], Meredith L McMorrow[SUP] 6 7 [/SUP], Nicole Wolter[SUP] 4 8 [/SUP], Jocelyn Moyes[SUP] 4 5 [/SUP], Maimuna Carrim[SUP] 4 8 [/SUP], Neil A Martinson[SUP] 9 10 [/SUP], Kathleen Kahn[SUP] 11 [/SUP], Limakatso Lebina[SUP] 9 [/SUP], Jacques D du Toit[SUP] 11 [/SUP], Thulisa Mkhencele[SUP] 4 [/SUP], Anne von Gottberg[SUP] 4 8 [/SUP], Cécile Viboud[SUP] 12 [/SUP], Penny L Moore[SUP] 2 3 13 [/SUP], Cheryl Cohen[SUP] 14 15 [/SUP]; PHIRST-C group



Collaborators, Affiliations
Abstract

Serum neutralizing antibodies (nAbs) induced by vaccination have been linked to protection against symptomatic and severe coronavirus disease 2019. However, much less is known about the efficacy of nAbs in preventing the acquisition of infection, especially in the context of natural immunity and against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune-escape variants. Here we conducted mediation analysis to assess serum nAbs induced by prior SARS-CoV-2 infections as potential correlates of protection against Delta and Omicron infections, in rural and urban household cohorts in South Africa. We find that, in the Delta wave, D614G nAbs mediate 37% (95% confidence interval: 34-40%) of the total protection against infection conferred by prior exposure to SARS-CoV-2, and that protection decreases with waning immunity. In contrast, Omicron BA.1 nAbs mediate 11% (95% confidence interval: 9-12%) of the total protection against Omicron BA.1 or BA.2 infections, due to Omicron's neutralization escape. These findings underscore that correlates of protection mediated through nAbs are variant specific, and that boosting of nAbs against circulating variants might restore or confer immune protection lost due to nAb waning and/or immune escape. However, the majority of immune protection against SARS-CoV-2 conferred by natural infection cannot be fully explained by serum nAbs alone. Measuring these and other immune markers including T cell responses, both in the serum and in other compartments such as the nasal mucosa, may be required to comprehensively understand and predict immune protection against SARS-CoV-2.


 
Back
Top Bottom